The moment of truth is almost here for rem-L and ARDS.
It's fair to say that Novartis will soon deliver an expert opinion on whether this ARDS treatment is worth pursuing or not. They have access to every minute detail of this product, making them far more informed than you, me, or our critics here on HC.
As I said months ago, I will shut the f* up about rem-L/ARDS if the umpire says no. Hopefully, our ever-present critics can do the same if the umpire says yes.
The moment of truth is almost here for rem-L and ARDS. It's fair...
-
- There are more pages in this discussion • 99 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
-0.040(3.76%) |
Mkt cap ! $1.170B | |||
| Open | High | Low | Value | Volume |
| $1.07 | $1.07 | $1.01 | $13.19M | 12.81M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 61090 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 239558 | 5 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |